HTG Molecular Diagnostics and Instituto Valenciano de Oncología Initiate Breast Cancer Recurrence Risk Collaboration
April 24 2017 - 8:00AM
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of
instruments, reagents and services for molecular profiling
applications, announced that it has entered into a research
collaboration agreement with Instituto Valenciano de Oncología
(IVO). The initial project, utilizing the HTG EdgeSeq
Oncology Biomarker Panel, will focus on the development and
validation of a breast cancer recurrence risk score, based on genes
that are differentially expressed between patients with low and
high risk of recurrence.
“The goal of this research collaboration is to develop a breast
cancer recurrence score, based on HTG’s technology, that is capable
of using a single, formalin-fixed, paraffin-embedded (FFPE) tissue
section that can be deployable for use by IVO and its affiliates
for testing of breast cancer patients in Spain,” said Dr. Jose
Antonio Lopez-Guerrero, Head of the Laboratory of Molecular Biology
at IVO. IVO, located in Valencia, Spain, is a private, non-profit
organization whose resources are used in the fight against cancer
including prevention, diagnosis, treatment, research, and
teaching.
“While other breast cancer recurrence risk scores are available
on market, we believe this effort could result in a more
cost-effective, decentralized laboratory solution that may allow
patients to more quickly make informed decisions regarding their
treatments,” explained TJ Johnson, President and Chief Executive
Officer of HTG. “We believe our HTG EdgeSeq chemistry is well
suited for the initial project because it will allow IVO to develop
their training set using a single, FFPE tissue section from each
previously assessed case.”
About HTG:
Headquartered in Tucson, Arizona, the mission of HTG Molecular
Diagnostics (HTG) is to empower precision medicine at the local
level. In 2013 the company commercialized its first instrument
platform and a portfolio of RNA assays that leveraged HTG's
original proprietary nuclease protection chemistry. Continuous
improvement led to the 2014 launch of the company’s HTG EdgeSeq
product line, which automates sample and targeted library
preparation for next-generation sequencing. Additional information
is available at www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements about the anticipated benefits or
results of our agreement with Instituto Valenciano de Oncología,
the capabilities of our technology, and our abilities to
successfully develop diagnostic products with our research partners
or otherwise and provide more cost-effective and decentralized
solutions for patient care. Words such as "believes,"
"anticipates," "plans," "expects," "intends," "will," "goal,"
"potential" and similar expressions are intended to identify
forward-looking statements, though not all forward-looking
statements necessarily contain these identifying words. These
forward-looking statements are based upon management's current
expectations, are subject to known and unknown risks, and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties,
including, without limitation, risks associated with the process of
developing and commercializing diagnostic products, our ability to
achieve and sustain sufficient market acceptance, and the
capabilities of our product and service solutions to keep pace with
rapidly changing technology and customer requirements. These and
other factors are described in greater detail in our filings with
the Securities and Exchange Commission, including without
limitation our Annual Report on Form 10-K for the Year ended
December 31, 2016. All forward-looking statements contained in this
press release speak only as of the date on which they were made,
and we undertake no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Contact:
Westwicke Partners
Jamar Ismail
Phone: 415-513-1282
Email: jamar.ismail@westwicke.com
TJ Johnson
President / CEO
HTG Molecular Diagnostics
Phone: 520-547-2827 x130
Email: tjjohnson@htgmolecular.com
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From May 2024 to Jun 2024
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From Jun 2023 to Jun 2024